ICICI Prudential Nifty Pharma Index Fund
- NAV as on 25 Sep 2026
- ₹20.41-0.10%1 day
- Return since launch
- 20.9%
- 52-week range
- ₹16.30 — ₹20.56
- AUM
- ₹157 Cr
ICICI Prudential Nifty Pharma Index Fund is a Sectoral-Pharma equity fund from ICICI Prudential Mutual Fund with ₹157 Cr under management, launched in 2022. Over three years it has returned 16.9% a year, against 21.1% for its category. The expense ratio is 1.19% and the SEBI riskometer reading is Very High.
Performance
ICICI Prudential Nifty Pharma Index Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +24.9% against +19.5% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 29.1% | +8.3 pts | 20.9% | 26.4% |
| 2Y | 17.4% | +0.6 pts | 16.8% | 15.2% |
| 3Y | 16.9% | −4.2 pts | 21.1% | 15.8% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 1.4% | +1.2 pts | 0.2% | -0.3% |
| 3M | 7.0% | +0.8 pts | 6.2% | 6.0% |
| 6M | 19.4% | −2.7 pts | 22.1% | 20.9% |
| 1Y | 24.9% | +4.0 pts | 20.9% | 19.5% |
| 2Y | 7.3% | −0.9 pts | 8.2% | 6.5% |
| 3Y | 21.0% | −0.1 pts | 21.1% | 20.1% |
Since launch (25 Nov 2022): 20.9%
Calendar-year returns
Category averageShow as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -3.2% | −1.1 pts | -2.0% |
| 2024 | 37.6% | −3.3 pts | 40.9% |
| 2023 | 31.9% | −4.3 pts | 36.2% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
1.18%
Expense ratio as on 24 Sep 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 0.89%
- Brokerage
- 0.01%
- Transaction charges
- 0.00%
- Statutory levies
- 0.28%
- Exit load
- 0%
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- NIFTY Pharma TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
| Ratio | Fund | Category avg | Read as |
|---|---|---|---|
| Alpha | -1.03 | 0.74 | Return earned above what the benchmark alone would have given. Higher is better. |
| Beta | 0.94 | 0.93 | How hard the fund moves when the market moves. Under 1 is steadier than the market. |
| Sharpe | 0.92 | 1.05 | Return earned for each unit of total risk taken. Higher is better. |
| Sortino | 1.64 | 1.63 | Return earned for each unit of downside risk. Higher is better. |
| Std. deviation | 15.94 | 15.68 | How widely monthly returns have varied around their own average. Lower is steadier. |
| Average of 5 category peers | |||
Portfolio
ICICI Prudential Nifty Pharma Index Fund portfolio
Portfolio as of 31 Aug 2026
Asset allocation
- Equity99.9%
- Other0.1%
Market cap split
- Large47.8%
- Mid45.0%
- Small7.1%
- P/E
- 41.41
- P/B
- 5.36
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 20.76% | ₹32.57 Cr | +21.33% | +21.81% | +21.97% |
| Divi's Laboratories Ltd. | Healthcare | 11.88% | ₹18.64 Cr | +9.48% | +9.65% | +9.95% |
| Cipla Ltd. | Healthcare | 7.83% | ₹12.29 Cr | +8.83% | +8.99% | +11.42% |
| Laurus Labs Ltd. | Healthcare | 7.36% | ₹11.55 Cr | +5.93% | +4.96% | +4.29% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 7.34% | ₹11.51 Cr | +5.16% | +5.37% | +4.76% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 6.95% | ₹10.91 Cr | +8.89% | +9.29% | +9.80% |
| Lupin Ltd. | Healthcare | 5.25% | ₹8.24 Cr | +6.16% | +6.62% | +5.85% |
| Aurobindo Pharma Ltd. | Healthcare | 4.69% | ₹7.36 Cr | +4.46% | +4.05% | +3.67% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 3.69% | ₹5.78 Cr | +3.83% | +3.81% | +3.70% |
| Alkem Laboratories Ltd. | Healthcare | 3.08% | ₹4.83 Cr | +3.60% | +3.91% | +3.64% |
| Biocon Ltd. | Healthcare | 2.90% | ₹4.56 Cr | +3.43% | +3.30% | +2.67% |
| Zydus Lifesciences Ltd. | Healthcare | 2.87% | ₹4.50 Cr | +3.02% | +2.73% | +3.13% |
| Ipca Laboratories Ltd. | Healthcare | 2.71% | ₹4.25 Cr | +2.37% | +2.52% | +2.46% |
| Mankind Pharma Ltd. | Healthcare | 2.70% | ₹4.24 Cr | +3.01% | +3.01% | +3.57% |
| Gland Pharma Ltd. | Healthcare | 2.27% | ₹3.56 Cr | +2.00% | +1.72% | +1.90% |
| Sai Life Sciences Ltd. | Healthcare | 1.99% | ₹3.12 Cr | — | — | — |
| Wockhardt Ltd. | Healthcare | 1.54% | ₹2.41 Cr | +1.88% | +1.33% | — |
| Ajanta Pharma Ltd. | Healthcare | 1.50% | ₹2.35 Cr | +1.38% | +1.50% | +1.33% |
| Piramal Pharma Ltd. | Healthcare | 1.32% | ₹2.07 Cr | +1.20% | +1.15% | — |
| Abbott India Ltd. | Healthcare | 1.31% | ₹2.06 Cr | +1.55% | +1.64% | +2.09% |
| Others | Others | 0.07% | ₹0.10 Cr | -0.49% | -0.13% | -0.70% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Divi's Laboratories Ltd. | 10.36% | 11.88% | +1.52% |
| Lupin Ltd. | 5.94% | 5.25% | -0.69% |
| Sun Pharmaceutical Industries Ltd. | 21.33% | 20.76% | -0.57% |
| Cipla Ltd. | 8.39% | 7.83% | -0.56% |
| Others | -0.51% | -1.01% | -0.50% |
| Alkem Laboratories Ltd. | 3.40% | 3.08% | -0.33% |
| Glenmark Pharmaceuticals Ltd. | 3.40% | 3.69% | +0.28% |
| Aurobindo Pharma Ltd. | 4.43% | 4.69% | +0.27% |
| Torrent Pharmaceuticals Ltd. | 7.60% | 7.34% | -0.27% |
| Gland Pharma Ltd. | 2.02% | 2.27% | +0.25% |
| Ipca Laboratories Ltd. | 2.46% | 2.71% | +0.25% |
| Laurus Labs Ltd. | 7.15% | 7.36% | +0.21% |
| Biocon Ltd. | 3.07% | 2.90% | -0.17% |
| Sai Life Sciences Ltd. | 1.84% | 1.99% | +0.15% |
| Abbott India Ltd. | 1.46% | 1.31% | -0.15% |
| Dr. Reddy's Laboratories Ltd. | 7.08% | 6.95% | -0.13% |
| Mankind Pharma Ltd. | 2.83% | 2.70% | -0.13% |
| Wockhardt Ltd. | 1.64% | 1.54% | -0.10% |
| Piramal Pharma Ltd. | 1.23% | 1.32% | +0.09% |
| Ajanta Pharma Ltd. | 1.48% | 1.50% | +0.02% |
| Zydus Lifesciences Ltd. | 2.85% | 2.87% | +0.02% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹3,579 Cr | 2.19% | 27.3% | 17.7% | 20.1% |
| ICICI Prudential Healthcare Fund | ₹6,996 Cr | 2.07% | 14.5% | 14.2% | 19.4% |
 SBI Healthcare Opportunities Fund | ₹5,796 Cr | 1.99% | 33.1% | 19.9% | 22.2% |
 Mirae Asset Healthcare Fund | ₹3,555 Cr | 2.03% | 29.9% | 18.4% | 19.7% |
 UTI Healthcare Fund | ₹1,444 Cr | 2.21% | 30.4% | 19.1% | 21.1% |
 LIC MF Healthcare Fund | ₹103 Cr | 2.67% | 28.7% | 16.9% | 17.9% |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index
Fund managers
- Ashwini Jemin BharuchaB.Com , M.Com , Inter CAPrior to Joining the ICICI Pru Mutual Fund he has worked with ICICI Pru AMC Treasury Mutual Fund Operations,
- Nishit PatelMr. Patel is a B.Com & Chartered AccountantPrior to joining ICICI Prudential Mutual fund, he has worked with K.K.Dand & Co.
- Venus AhujaChartered Accountant and B.ComMr. Venus Ahuja, who was previously part of the Investment Monitoring Team at ICICI AMC, has now been appointed as a Fund Manager and Dealer in the Investments Department of ICICI AMC
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months19.40% absolute | ₹60,000 | ₹71,640 | 19.40% | |
| 1 year24.89% annualised | ₹1,20,000 | ₹1,37,475 | 14.56% | |
| 3 years21.00% annualised | ₹3,60,000 | ₹5,04,335 | 40.09% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.